Pitt Shield

Noninvasive Ultrasonic Drug Uncaging Maps Whole-Brain Functional Networks.

Authors: Wang JB, Aryal M, Zhong Q, Vyas DB, Airan RD

Being able to noninvasively modulate brain activity, where and when an experimenter desires, with an immediate path toward human translation is a long-standing goal for neuroscience. To enable robust perturbation of brain activity while leveraging the ability of focused ultrasound to deliver energy to any point of the brain noninvasively, we have developed biocompatible and clinically translatable nanoparticles that allow ultrasound-induced uncaging of neuromodulatory drugs. Utilizing the anesthetic propofol, together with electrophysiological and imaging assays, we show that the neuromodulatory effect of ultrasonic drug uncaging is limited spatially and temporally by the size of the ultrasound focus, the sonication timing, and the pharmacokinetics of the uncaged drug. Moreover, we see secondary effects in brain regions anatomically distinct from and functionally connected to the sonicated region, indicating that ultrasonic drug uncaging could noninvasively map the changes in functional network connectivity associated with pharmacologic action at a particular brain target.

Introduction

Purpose Drug delivery WITHOUT BBB opening
Study Objective Develop and demonstrate biocompatible nanoparticles that enable focused-ultrasound-triggered uncaging of neuromodulatory drugs to noninvasively and precisely modulate brain activity and map functional networks.
Animal model / Human subject Mice (wildtype), strain: wildtype (specific strain not specified), age: not specified, sex: not specified
Disease model healthy
MRI or image guidance method Not specified in the provided text
Targeted brain region(s) Not Specified In Provided Text
Target coordinates Not provided in the paper text.
Cargo name and characteristics Propofol — small-molecule intravenous general anesthetic (2,6‑diisopropylphenol); GABA-A receptor positive allosteric modulator used as the neuromodulatory payload for ultrasonic uncaging; rapid onset and short duration pharmacokinetics enabling temporally precise brain modulation.
Route of administration intravenous

Outcomes and Safety

Summary of Outcomes Nanoparticle-mediated ultrasonic uncaging of propofo.
Duration of biological effect Not specified
Safety-related matter No safety issues or adverse effects are reported; the nanoparticles are described as biocompatible and clinically translatable.

Brain Region

Ultrasound Parameters

Ultrasound instrument Not specified in provided text
FUS Frequency 650 kHz
FUS Intensity Not specified in provided text.
FUS Pressure 1.8 MPa
FUS Mode pulsed
Pulse duration 100 ms
Duration of a single FUS session Not specified in provided text
Focal Characteristics Not specified in the provided text
Treatment frequency multiple

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search